Akèy › Kansè Poumon ki pa ti selil › Massachusetts

Etid klinik pou Kansè Poumon ki pa ti selil nan Massachusetts

102 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan Massachusetts.

Vil nan Massachusetts

Tèks ofisyèl etid la (Anglè)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Beverly Hospital, Beverly
Boston Medical Center, Boston
Beth Israel Deaconess Medical Center, Boston
ak 8 plis

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04267848

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Massachusetts General Hospital ( Site 0136), Boston
Dana Farber Cancer Hospital ( Site 0155), Boston

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06623422

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

University of Massachusetts Memorial Medical Center, Worcester

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06472245

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Massachusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston

Ap rekriteFaz 1/2

Laj 12 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04585750

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Massachusetts General Hospital, Boston

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06465069

Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

Massachusetts General Hospital, Boston

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07751042

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Exelixis Clinical Site #7, Boston

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT05176483

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

Brigham and Women's Hospital, Boston
Dana-Farber Cancer Institute, Boston
Dana-Farber Cancer Institute - Chestnut Hill, Newton

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07090499

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Massachusetts General Hospital, Boston
Dana-Farber Cancer Insitute, Boston

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06625775

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Beverly Hospital, Beverly
Lahey Clinic, Burlington
Addison Gilbert Hospital, Gloucester
ak 3 plis

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06498635

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Local Institution - 0603, Boston

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07361497

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

Dana-Farber Cancer Institute, Boston

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06765109

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Research Site, Boston
Research Site, Boston

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT05877599

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Dana-Farber Cancer Institute /ID# 278417, Boston

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT06772623

A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

Massachusetts General Hospital, Boston

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07578571

A Study of PHN-012 in Patients With Advanced Solid Tumors

PHN-012-001 Site, Boston

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07127874

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

University of Massachusetts Worcester, Worcester

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07144280

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Boston Medical Center, Boston

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05498428

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Reliant Medical Group Inc, Worcester

Ap rekriteFaz 3

Laj 18 a 100 · Tout sèks · Mizajou Sep 25, 2026 · NCT05920356

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Research Site, Boston

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06218914

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Southcoast Centers for Cancer Care, Fairhaven
Southcoast Centers for Cancer Care, Fall River

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06758401

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Boston University Medical Center, Boston
Beth Israel Deaconess Medical Center, Boston
Dana Farber Cancer Institute, Boston

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06667076

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

Beth Israel Deaconess Medical Center, Boston

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06667908

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Lahey Hospital & Medical Center, Burlington
Reliant Medical Group, Worcester

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06890598

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Tufts Medical Center, Boston

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06047379

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Massachusetts General Hospital Cancer Center, Boston

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT03191149

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Research Site, Boston
Research Site, Boston

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT06357533

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Research Site, Boston

Ap rekriteFaz 2

Laj 18 a 95 · Tout sèks · Mizajou Sep 23, 2026 · NCT05061550

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Dana Farber Cancer Institute, Boston

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06128551

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Dana-Farber Cancer Institute, Boston

Ap rekriteFaz 2/3

Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07100080

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Local Institution - 0019, Boston

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06875310

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Massachusetts General Hospital, Boston
Dana-Farber Cancer Institute, Boston

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT05983432

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

Massachusetts General Hospital - Main Campus, Boston

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT07629960

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Clinical Study Site, Boston
Clinical Study Site, Brighton
Clinical Study Site, Foxborough
ak 4 plis

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT06767514

A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

Dana-Farber Cancer Institute, Boston

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT06855771

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Dana-Farber Cancer Institute, Boston

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07349537

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

Dana-Farber Cancer Institute, Boston

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07195695

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Dana-Farber Cancer Institute, Boston

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT05786924

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Dana-Farber Cancer Institute, Boston
Dana-Farber Cancer Institute at St. Elizabeths Medical Center, Brighton
Brigham and Womens/Mass General Health Care Center at Foxborough, Foxborough
ak 3 plis

Ap rekriteFaz 2/3

Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT04613596

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

Dana-Farber Cancer Institute, Boston

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06899126

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.